MannKind Shares Jump After United Therapeutics Collaboration on Ralinepag DPI
MannKind's stock climbed sharply in morning trading after the company disclosed it is developing a dry powder inhalation formulation of ralinepag, MNKD-1501, for United Therapeutics under an expanded collaboration. The arrangement includes an immediate $5 million payment, potential development milestones up to $35 million and a 10% royalty on net s…